Azamian Bobak R.'s Form 4 filing
Tarsus Pharmaceuticals, Inc. (TARS) · filed Mar 19, 2026
- Accession no.
- 0001827672-26-000007
- Filed
- Mar 19, 2026
- Trade date
- Mar 17-19, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $2.36M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Azamian Bobak R.CIK 0001827672 | Director, Officer (President/CEO and Board Chair) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | Common Stock | SSaleDisposed | −10,972 | $69.42 | −$761,676.24 | 57,052 | Direct | |
| Mar 18, 2026 | Common Stock | SSaleDisposed | −11,667 | $68.71 | −$801,639.57 | 45,385 | Direct | |
| Mar 19, 2026 | Common Stock | SSaleDisposed | −11,964 | $67.00 | −$801,588 | 33,421 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.